Kadmon Holdings Inc (NYSE:KDMN) – Equities researchers at Jefferies Group issued their FY2022 earnings estimates for shares of Kadmon in a research note issued on Friday, Zacks Investment Research reports. Jefferies Group analyst B. Amin expects that the company will post earnings of ($1.58) per share for the year.
Several other research analysts have also weighed in on KDMN. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, November 17th. Zacks Investment Research raised Kadmon from a “sell” rating to a “hold” rating in a research report on Tuesday, November 21st. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Kadmon currently has an average rating of “Hold” and an average target price of $8.65.
Kadmon (KDMN) opened at $4.84 on Monday. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86. The firm has a market capitalization of $380.63 and a PE ratio of -2.77.
Hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. acquired a new position in Kadmon in the 2nd quarter worth about $114,000. Bank of New York Mellon Corp acquired a new position in shares of Kadmon during the 3rd quarter valued at about $119,000. Old West Investment Management LLC acquired a new position in shares of Kadmon during the 3rd quarter valued at about $169,000. Wells Fargo & Company MN increased its holdings in shares of Kadmon by 17.0% during the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock valued at $234,000 after acquiring an additional 8,742 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Kadmon by 151.2% during the 4th quarter. BlackRock Inc. now owns 208,190 shares of the company’s stock valued at $754,000 after acquiring an additional 125,308 shares during the last quarter. 51.91% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/13/kadmon-holdings-inc-kdmn-to-post-fy2022-earnings-of-1-58-per-share-jefferies-group-forecasts.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Get a free copy of the Zacks research report on Kadmon (KDMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.